Mogadon (Nitrazepam)

Nitrazepam is indicated for conditions involving excessive central nervous system activity, primarily within the sleep and anxiety disorder categories.

• Insomnia: helps initiate and maintain sleep, reducing nighttime awakenings.
• Anxiety: alleviates excessive worry and tension, promoting a calmer mental state.
• Severe anxiety episodes: provides rapid relief of intense anxiety symptoms when other treatments are insufficient.

• Nitrazepam acts as a positive allosteric modulator at the γ‑aminobutyric acid type A (GABA‑A) receptor complex. By binding to the benzodiazepine site, it enhances the affinity of GABA for its receptor, increasing chloride ion influx and hyperpolarizing neuronal membranes. This potentiation of inhibitory neurotransmission reduces neuronal excitability, producing sedative, anxiolytic, muscle‑relaxant and anticonvulsant effects. The effect is dose‑dependent and reversible upon discontinuation.

Nitrazepam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Drowsiness: feeling of sleepiness during daytime.
• Fatigue: reduced energy levels.
• Dizziness: sensation of light‑headedness.
• Impaired coordination: clumsiness or balance problems.
• Memory disturbances: difficulty recalling recent events.
• Headache: mild to moderate head pain.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing, especially with other depressants.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Depression or suicidal thoughts: worsening mood or emergence of self‑harm ideation.
• Paradoxical agitation: increased anxiety, aggression, or hostility.
• Dependence and withdrawal: physical dependence with withdrawal symptoms upon abrupt cessation.

When prescribing nitrazepam, clinicians should consider several safety measures to minimise risks.

• Avoid abrupt discontinuation: taper the dose gradually to prevent withdrawal symptoms.
• Use caution in elderly: increased sensitivity may lead to falls or confusion.
• Monitor respiratory function: especially in patients with COPD or when combined with other depressants.
• Limit alcohol consumption: concurrent use can intensify sedation and respiratory depression.
• Assess hepatic and renal function: impaired metabolism may increase drug exposure.
• Store at room temperature: keep in the original container, protect from moisture and light.

Nitrazepam can interact with various medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Opioids: combined CNS depression may cause profound respiratory depression.
• Other benzodiazepines: additive sedative effects increase risk of overdose.
• Alcohol: synergistic sedation and impaired psychomotor performance.
• Barbiturates: enhanced CNS depression leading to severe sedation.
• Antihistamines with sedative properties: increased drowsiness and impaired alertness.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise nitrazepam plasma levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Antidepressants (e.g., fluoxetine, sertraline): potential for increased sedation.
• Anticonvulsants (e.g., valproate): may affect plasma concentrations.
• Antihypertensives: enhanced hypotensive effect due to central nervous system depression.